60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on developing innovative therapies primarily targeting cancer and other serious medical conditions. The company emphasizes research and development to bring novel treatment options to market, leveraging advanced scientific approaches to improve patient outcomes.
Company News
60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.
60 Degrees Pharmaceuticals has introduced a new 8-count bottle format for its malaria prevention drug ARAKODA, expanding options for healthcare professionals and travelers.
Sixty Degrees Pharmaceuticals announced that it will import a limited quantity of KODATEF® (tafenoquine) from Australia to ensure the continuity of ARAKODA® (tafenoquine) supply in the U.S. ARAKODA and KODATEF are identical products, and the company is taking this proactive step to maintain the availability of tafenoquine for malaria prophylaxis.
U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.
60 Degrees Pharmaceuticals announced a promotional pilot for its antimalarial drug ARAKODA, which aims to increase brand awareness and utilization through virtual sales outreach and a co-pay program.
